First-Line Ipilimumab with Nivolumab versus Immune Checkpoint Inhibitors with Tyrosine Kinase Inhibitors in Patients with Intermediate- or Poor-Risk Metastatic Clear Cell Renal Cell Carcinoma. Journal of Kidney Cancer, [S. l.], v. 12, n. 2, p. 27–36, 2025. DOI: 10.15586/jkcvhl.v12i2.387. Disponível em: https://jkcvhl.com/~jkcvhlco/index.php/jkcvhl/article/view/387. Acesso em: 17 apr. 2026.